Erik C Bottger

Summary

Affiliation: University of Zurich
Country: Switzerland

Publications

  1. ncbi The ribosome as a drug target
    Erik C Bottger
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006, Switzerland
    Trends Biotechnol 24:145-7. 2006
  2. pmc Fitness cost of chromosomal drug resistance-conferring mutations
    Peter Sander
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, CH 8028 Zurich, Switzerland
    Antimicrob Agents Chemother 46:1204-11. 2002
  3. pmc Structural basis for selectivity and toxicity of ribosomal antibiotics
    E C Bottger
    Institut fur Medizinische Mikrobiologie, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    EMBO Rep 2:318-23. 2001
  4. ncbi Antimicrobial agents targeting the ribosome: the issue of selectivity and toxicity - lessons to be learned
    E C Bottger
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006, Zurich, Switzerland
    Cell Mol Life Sci 64:791-5. 2007
  5. ncbi The molecular basis for A-site mutations conferring aminoglycoside resistance: relationship between ribosomal susceptibility and X-ray crystal structures
    Peter Pfister
    Institute of Medical Microbiology, University of Zurich, Gloriastrasse 30 32, 8028 Zurich, Switzerland
    Chembiochem 4:1078-88. 2003
  6. pmc Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin
    Tanja Matt
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, 8006 Zurich, Switzerland
    Proc Natl Acad Sci U S A 109:10984-9. 2012
  7. pmc Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity
    Sven N Hobbie
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 32, CH 8006 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:20888-93. 2008
  8. pmc Analysis of the contribution of individual substituents in 4,6-aminoglycoside-ribosome interaction
    Sven N Hobbie
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastr 30 32, CH 8006 Zurich, Switzerland
    Antimicrob Agents Chemother 49:5112-8. 2005
  9. pmc 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A-->G
    Peter Pfister
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    Proc Natl Acad Sci U S A 102:5180-5. 2005
  10. pmc Structure-activity relationships among the kanamycin aminoglycosides: role of ring I hydroxyl and amino groups
    Sumantha Salian
    Laboratorium fur Organische Chemie, ETH Zurich, Zurich, Switzerland
    Antimicrob Agents Chemother 56:6104-8. 2012

Collaborators

Detail Information

Publications66

  1. ncbi The ribosome as a drug target
    Erik C Bottger
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006, Switzerland
    Trends Biotechnol 24:145-7. 2006
    ..5A resolution and one on the identification of functionally relevant sites within the small subunit rRNA, illustrate the importance of interdisciplinary approaches in exploiting the ribosome as a drug target...
  2. pmc Fitness cost of chromosomal drug resistance-conferring mutations
    Peter Sander
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, CH 8028 Zurich, Switzerland
    Antimicrob Agents Chemother 46:1204-11. 2002
    ..These results argue against expectations that link decreased levels of antibiotic consumption with the decline in the level of resistance...
  3. pmc Structural basis for selectivity and toxicity of ribosomal antibiotics
    E C Bottger
    Institut fur Medizinische Mikrobiologie, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    EMBO Rep 2:318-23. 2001
    ..This has important implications for drug specificity and toxicity. Together with recent data on the structure of ribosomal subunits these data provide the basis for development of new ribosomal antibiotics by rationale drug design...
  4. ncbi Antimicrobial agents targeting the ribosome: the issue of selectivity and toxicity - lessons to be learned
    E C Bottger
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006, Zurich, Switzerland
    Cell Mol Life Sci 64:791-5. 2007
  5. ncbi The molecular basis for A-site mutations conferring aminoglycoside resistance: relationship between ribosomal susceptibility and X-ray crystal structures
    Peter Pfister
    Institute of Medical Microbiology, University of Zurich, Gloriastrasse 30 32, 8028 Zurich, Switzerland
    Chembiochem 4:1078-88. 2003
    ....
  6. pmc Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin
    Tanja Matt
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, 8006 Zurich, Switzerland
    Proc Natl Acad Sci U S A 109:10984-9. 2012
    ..Together with 3D structures of apramycin-ribosome complexes at 3.5-Å resolution, our results provide a conceptual framework for further development of less toxic aminoglycosides by hypothesis-driven chemical synthesis...
  7. pmc Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity
    Sven N Hobbie
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 32, CH 8006 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:20888-93. 2008
    ....
  8. pmc Analysis of the contribution of individual substituents in 4,6-aminoglycoside-ribosome interaction
    Sven N Hobbie
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastr 30 32, CH 8006 Zurich, Switzerland
    Antimicrob Agents Chemother 49:5112-8. 2005
    ..Overall, the set of interactions forming the complex between drug substituents and nucleotides of the A site constitutes a network in which the interactions can partly compensate for each other when they are disrupted...
  9. pmc 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A-->G
    Peter Pfister
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    Proc Natl Acad Sci U S A 102:5180-5. 2005
    ....
  10. pmc Structure-activity relationships among the kanamycin aminoglycosides: role of ring I hydroxyl and amino groups
    Sumantha Salian
    Laboratorium fur Organische Chemie, ETH Zurich, Zurich, Switzerland
    Antimicrob Agents Chemother 56:6104-8. 2012
    ..Position 2' forms an intramolecular H bond with O5 of ring II, helping the relative orientations of the two rings with respect to each other. This bond becomes critical for drug activity when a 6'-OH substituent is present...
  11. pmc Mitochondrial deafness alleles confer misreading of the genetic code
    Sven N Hobbie
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 32, CH 8006 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:3244-9. 2008
    ..This finding suggests misreading of the genetic code as an important molecular mechanism in disease pathogenesis...
  12. pmc Mutation K42R in ribosomal protein S12 does not affect susceptibility of Mycobacterium smegmatis 16S rRNA A-site mutants to 2-deoxystreptamines
    Sarath K Kalapala
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland
    PLoS ONE 5:e11960. 2010
    ..RpsL K42R substitution was found not to affect the drug resistance pattern associated with mutational alterations in 16S rRNA H44...
  13. pmc Evaluation of Cobas TaqMan MTB for direct detection of the Mycobacterium tuberculosis complex in comparison with Cobas Amplicor MTB
    Guido V Bloemberg
    Institut fur Medizinische Mikrobiologie, Zurich, Switzerland
    J Clin Microbiol 51:2112-7. 2013
    ..6% and a specificity of 94.6% for the 305 nonrespiratory specimens. We conclude that the Cobas TaqMan MTB assay is a significantly improved tool for the direct detection of M. tuberculosis DNA in clinical specimens...
  14. ncbi The structural basis of macrolide-ribosome binding assessed using mutagenesis of 23S rRNA positions 2058 and 2059
    Peter Pfister
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8028 Zurich, Switzerland
    J Mol Biol 342:1569-81. 2004
    ..Our genetic data show no support for a derivatized-macrolide binding site that has been proposed to be located further down the tunnel...
  15. pmc Phylogenetic sequence variations in bacterial rRNA affect species-specific susceptibility to drugs targeting protein synthesis
    Subramanian Akshay
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, 8006 Zurich, Switzerland
    Antimicrob Agents Chemother 55:4096-102. 2011
    ..Our results provide a rationale for differences in species-specific drug susceptibility patterns and species-specific resistance phenotypes associated with mutational alterations in the drug binding pocket...
  16. ncbi Lack of mismatch correction facilitates genome evolution in mycobacteria
    Burkhard Springer
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 3028 Zürich, Switzerland
    Mol Microbiol 53:1601-9. 2004
    ..Together, the lack of mismatch correction and a high stringency of initiation of homologous recombination provide an adequate strategy for mycobacterial genome evolution, which occurs by gene duplication and divergent evolution...
  17. pmc Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin
    Rashid Akbergenov
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, 8006 Zurich, Switzerland
    Antimicrob Agents Chemother 55:4712-7. 2011
    ....
  18. pmc Characterization of the mycobacterial NER system reveals novel functions of the uvrD1 helicase
    Carolin Güthlein
    Institut fur Medizinische Mikrobiologie, University of Zurich, Gloriastrasse 30 32, CH 8006, Zurich, Switzerland
    J Bacteriol 191:555-62. 2009
    ..This implies that in mycobacteria (which lack the postreplicative mismatch repair system) NER, and particularly the UvrD1 helicase, is involved in the processing of a subset of recombination-associated mismatches...
  19. pmc Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria
    Sven N Hobbie
    Institut fur Medizinische Mikrobiologie, Universität Zürich and Laboratorium für Organische Chemie, ETH Zurich, Switzerland
    Nucleic Acids Res 35:6086-93. 2007
    ..The activities of the hybrid ribosomes indicate that helix 44 of the rRNA decoding site behaves as an autonomous domain, which can be exchanged between ribosomes of different phylogenetic domains for study of function...
  20. pmc Evaluation of the Bruker MALDI Biotyper for Identification of Fastidious Gram-Negative Rods
    Bettina Schulthess
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
    J Clin Microbiol 54:543-8. 2016
    ....
  21. doi Evaluation of the AID ESBL line probe assay for rapid detection of extended-spectrum β-lactamase (ESBL) and KPC carbapenemase genes in Enterobacteriaceae
    Guido V Bloemberg
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, 8006 Zurich, Switzerland
    J Antimicrob Chemother 69:85-90. 2014
    ..This study aimed at evaluating the AID ESBL line probe assay for the detection of extended-spectrum β-lactamase (ESBL) and KPC carbapenemase genes in Enterobacteriaceae...
  22. doi Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST
    Michael Hombach
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Nationales Zentrum für Mykobakterien, Zurich, Switzerland
    Int J Med Microbiol 303:270-6. 2013
    ..avium, M. intracellulare, and M. kansasii that may aid the definition of CBPs when correlating in vitro drug susceptibility with clinical outcomes in future studies...
  23. pmc Integrating the Xpert MTB/RIF assay into a diagnostic workflow for rapid detection of Mycobacterium tuberculosis in a low-prevalence area
    Vanessa Deggim
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland
    J Clin Microbiol 51:2396-9. 2013
    ..The results showed that replacing smear microscopy with the Xpert MTB/RIF assay facilitates laboratory handling and improves the sensitivity and specificity of Mycobacterium tuberculosis detection...
  24. pmc Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis
    Thomas Grau
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
    Antimicrob Agents Chemother 56:1142-5. 2012
    ....
  25. pmc A mycobacterial smc null mutant is proficient in DNA repair and long-term survival
    Carolin Güthlein
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, 8006 Zurich, Switzerland
    J Bacteriol 190:452-6. 2008
    ..Surprisingly, inactivation of smc did not result in recognizable phenotypes in hallmark assays characteristic for the function of these genes. This is in contrast to data for smc null mutants in other species...
  26. pmc Recognition of potentially novel human disease-associated pathogens by implementation of systematic 16S rRNA gene sequencing in the diagnostic laboratory
    Peter M Keller
    University of Zurich, Institute of Medical Microbiology, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    J Clin Microbiol 48:3397-402. 2010
    ..For 30 of 60 isolates, clinical relevance was evaluated; 18 of the 30 isolates analyzed were considered to be associated with human disease...
  27. pmc Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping
    Burkhard Springer
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland
    J Clin Microbiol 46:4064-7. 2008
    ....
  28. pmc Diagnostic Molecular Mycobacteriology in Regions With Low Tuberculosis Endemicity: Combining Real-time PCR Assays for Detection of Multiple Mycobacterial Pathogens With Line Probe Assays for Identification of Resistance Mutations
    Vanessa Deggim-Messmer
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, 8006 Zurich, Switzerland
    EBioMedicine 9:228-37. 2016
    ..Our findings suggest a diagnostic algorithm to largely replace lengthy culture-based techniques by rapid molecular-based methods. ..
  29. pmc Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST
    Peter M Keller
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland Nationales Referenzzentrum für Mykobakterien, Universitat Zurich, Zurich, Switzerland
    Antimicrob Agents Chemother 59:4352-5. 2015
    ..65 mg/liter (median, 0.4 mg/liter) and an epidemiological cutoff (ECOFF) of 1.6 mg/liter; for delamanid, a mean wild-type drug MIC of 0.013 mg/liter (median, 0.01 mg/liter) and an ECOFF of 0.04 mg/liter were determined...
  30. doi Aminoglycoside-modifying enzymes determine the innate susceptibility to aminoglycoside antibiotics in rapidly growing mycobacteria
    Florian P Maurer
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland Nationales Zentrum für Mykobakterien, Zurich, Switzerland
    J Antimicrob Chemother 70:1412-9. 2015
    ..abscessus infections, although little is known about intrinsic drug resistance mechanisms. We investigated the role of chromosomally encoded putative aminoglycoside-modifying enzymes (AME) in AGA susceptibility in M. abscessus...
  31. pmc Standardisation of disk diffusion results for antibiotic susceptibility testing using the sirscan automated zone reader
    Michael Hombach
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, 8006 Zurich, Switzerland
    BMC Microbiol 13:225. 2013
    ..This study evaluated accuracy, reproducibility, and precision of automated inhibition zone reading using the "Sirscan automatic" zone reader (i2a, Perols Cedex, France)...
  32. doi Automated quantitative drug susceptibility testing of non-tuberculous mycobacteria using MGIT 960/EpiCenter TB eXiST
    Katja Lucke
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Nationales Zentrum für Mykobakterien, Zurich, Switzerland
    J Antimicrob Chemother 67:154-8. 2012
    ..The aim of this study was to investigate the suitability of the MGIT 960/TB eXiST system for quantitative DST of NTM...
  33. pmc Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant
    Peter M Keller
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    BMC Microbiol 8:120. 2008
    ..All vaccine substrains in use stem from one source, strain Bacille Calmette-Guérin. However, they differ in regions of genomic deletions, antigen expression levels, immunogenicity, and protective efficacy...
  34. pmc Performance of Copan WASP for Routine Urine Microbiology
    Chantal Quiblier
    Universitat Zurich, Institut fur Medizinische Mikrobiologie, Zurich, Switzerland
    J Clin Microbiol 54:585-92. 2016
    ..4% of the samples), and pathogens (for 3.4% of the samples). The results of this study point to an improved quality of microbiological analyses and laboratory reports when using automated sample processing by WASP and WASPLab. ..
  35. doi Relative contribution of biological variation and technical variables to zone diameter variations of disc diffusion susceptibility testing
    Michael Hombach
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, 8006 Zurich, Switzerland
    J Antimicrob Chemother 71:141-51. 2016
    ..It is deemed to originate from factors such as genetic background or metabolic state. This study analysed the relative contribution of different technical and biological factors to total disc diffusion variation...
  36. doi Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis
    Dmitri Shcherbakov
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Schweiz Nationales Zentrum für Mykobakterien, Universitat Zurich, Zurich, Schweiz Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
    Mol Microbiol 77:830-40. 2010
    ..The same types of resistance and associated mutations can be found in M. tuberculosis in clinical isolates, suggesting that compensatory evolution contributes to the spread of drug-resistant tuberculosis disease. ..
  37. pmc Lack of antimicrobial bactericidal activity in Mycobacterium abscessus
    Florian P Maurer
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland Nationales Zentrum für Mykobakterien, Universitat Zurich, Zurich, Switzerland
    Antimicrob Agents Chemother 58:3828-36. 2014
    ..abscessus infection. Our findings suggest that chromosomally encoded drug-modifying enzymes play an important role in the lack of aminoglycoside bactericidal activity against rapidly growing mycobacteria. ..
  38. pmc Evaluation of the Bruker MALDI Biotyper for identification of Gram-positive rods: development of a diagnostic algorithm for the clinical laboratory
    Bettina Schulthess
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
    J Clin Microbiol 52:1089-97. 2014
    ..Based on our results, we suggest an identification algorithm for the clinical laboratory combining MALDI-TOF MS with nucleic acid sequencing. ..
  39. doi Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41)
    Florian P Maurer
    Institut fur Medizinische Mikrobiologie, Nationales Zentrum für Mykobakterien, Universitat Zurich, 8006 Zurich, Switzerland
    J Antimicrob Chemother 67:2606-11. 2012
    ..abscessus infection undergoing clarithromycin therapy, M. abscessus acquires clarithromycin resistance mutations in the rrl gene in addition to the presence of an inducible Erm(41) methylase...
  40. pmc Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens
    Pål Johansen
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Vaccine Immunol 18:907-13. 2011
    ..In conclusion, our results suggest that phagosome maturation and lysosomal delivery of BCG facilitate mycobacterial antigen presentation and enhance immunogenicity...
  41. pmc Stabilization of the genome of the mismatch repair deficient Mycobacterium tuberculosis by context-dependent codon choice
    Roger M Wanner
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    BMC Genomics 9:249. 2008
    ..Here, we analyzed how these opposing forces shaped genome stability in the human pathogen Mycobacterium tuberculosis. M. tuberculosis lacks a mismatch repair system, and this renders nucleotide repeats particularly unstable...
  42. ncbi Tuberculosis: drug resistance, fitness, and strategies for global control
    Erik C Bottger
    Nationales Zentrum für Mykobakterien, Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 32, 8006, Zurich, Switzerland
    Eur J Pediatr 167:141-8. 2008
    ....
  43. pmc Binding of neomycin-class aminoglycoside antibiotics to mutant ribosomes with alterations in the A site of 16S rRNA
    Sven N Hobbie
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastr 30 32, CH 8006 Zurich, Switzerland
    Antimicrob Agents Chemother 50:1489-96. 2006
    ..U1495 wobble base pair to the Watson-Crick interaction pair 1406C-1495G yields ribosomal drug susceptibilities to 4,5-aminoglycosides comparable to those seen with the wild-type A site...
  44. pmc Practical approach for reliable detection of AmpC beta-lactamase-producing Enterobacteriaceae
    Silke Polsfuss
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastr 30 32, 8006 Zurich, Switzerland
    J Clin Microbiol 49:2798-803. 2011
    ..4 and 100%, respectively, with respect to the studied isolates. The phenotypic methods used in the AmpC algorithm are simple to perform and easy to implement in the diagnostic laboratory...
  45. doi LspA inactivation in Mycobacterium tuberculosis results in attenuation without affecting phagosome maturation arrest
    Silvana K Rampini
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 32, CH 8006 Zurich, Switzerland
    Microbiology 154:2991-3001. 2008
    ..These observations demonstrate severe attenuation even in the presence of arrested phagosome maturation, and point to a role for the early phagosome in growth restriction of the M. tuberculosis lspA mutant...
  46. ncbi Identification of moulds in the diagnostic laboratory--an algorithm implementing molecular and phenotypic methods
    Diana E Ciardo
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, 8006 Zurich, Switzerland
    Diagn Microbiol Infect Dis 59:49-60. 2007
    ..Based on these results, we propose a diagnostic algorithm for the effective use of both phenotypic and genetic procedures for identification of moulds in the diagnostic laboratory...
  47. pmc The Resistant-Population Cutoff (RCOFF): a New Concept for Improved Characterization of Antimicrobial Susceptibility Patterns of Non-Wild-Type Bacterial Populations
    Giorgia Valsesia
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
    J Clin Microbiol 53:1806-11. 2015
    ..This should improve the correlation of in vitro AST data and distinct antibiotic resistance mechanisms with clinical outcome facilitating the setting and validation of CBPs. ..
  48. pmc A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing
    Giorgia Valsesia
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
    J Clin Microbiol 53:1812-22. 2015
    ..coli and AmpC-positive K. pneumoniae; and broad-spectrum beta-lactamase (BSBL)-positive E. coli. RCOFFs and ECOFFs are instrumental for a systematic characterization of associations between resistotypes and wild-type populations. ..
  49. pmc Identification and evaluation of improved 4'-O-(alkyl) 4,5-disubstituted 2-deoxystreptamines as next-generation aminoglycoside antibiotics
    Stefan Duscha
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland
    MBio 5:e01827-14. 2014
    ..The favorable biocompatibility profile combined with the promising antibacterial activity emphasizes the potential of next-generation aminoglycosides in the treatment of infectious diseases without the risk of ototoxicity...
  50. pmc Integrating forecast probabilities in antibiograms: a way to guide antimicrobial prescriptions more reliably?
    Florian P Maurer
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland
    J Clin Microbiol 52:3674-84. 2014
    ..Clinicians should be aware of the significantly increased risk of erroneous AST reports for isolates producing beta-lactamases, particularly ESBL and AmpC. Including probability indicators for interpretation would improve AST reports. ..
  51. pmc Use of the Bruker MALDI Biotyper for identification of molds in the clinical mycology laboratory
    Bettina Schulthess
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
    J Clin Microbiol 52:2797-803. 2014
    ..0 and a species cutoff of 1.7. However, expansion of the database is required to reduce the number of nonidentified isolates. ..
  52. doi Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli
    Michael Hombach
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland
    J Antimicrob Chemother 67:622-32. 2012
    ..The aim of this study was to analyse the effects of clinical breakpoint changes in CLSI 2010 and 2011 guidelines and EUCAST 2011 guidelines on antibiotic susceptibility testing (AST) reports...
  53. pmc Genetic reconstruction of protozoan rRNA decoding sites provides a rationale for paromomycin activity against Leishmania and Trypanosoma
    Sven N Hobbie
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
    PLoS Negl Trop Dis 5:e1161. 2011
    ....
  54. pmc Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation
    Burkhard Springer
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8006 Zurich, Switzerland
    J Clin Microbiol 47:1773-80. 2009
    ..In-depth comparative analysis of a range of well-characterized susceptible and resistant clinical isolates has allowed us to propose conditions for testing and to develop criteria for interpretation...
  55. ncbi A recA deletion mutant of Mycobacterium bovis BCG confers protection equivalent to that of wild-type BCG but shows increased genetic stability
    Peter Sander
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, CH 8028, Zurich, Switzerland
    Vaccine 21:4124-7. 2003
    ..The availability of a genetically stable, fully immunogenic BCG is important for the future development of BCG as a live vaccine...
  56. doi Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591
    Anna Rominski
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, Zurich 8006, Switzerland
    J Antimicrob Chemother . 2016
    ..The aim of this study was to investigate the role of the MAB_0591 (arrMab)-encoded rifampicin ADP-ribosyltransferase (Arr_Mab) in innate high-level rifampicin resistance in M. abscessus...
  57. pmc Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis
    Guido V Bloemberg
    University of Zurich, Zurich, Switzerland
    N Engl J Med 373:1986-8. 2015
    ..Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid. ..
  58. pmc Standardization of Operator-Dependent Variables Affecting Precision and Accuracy of the Disk Diffusion Method for Antibiotic Susceptibility Testing
    Michael Hombach
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland
    J Clin Microbiol 53:3864-9. 2015
    ..e., the individual standard deviations, compared to the standard deviations for the manual method, and the mean of the standard deviations of all operators together, i.e., total methodological variation...
  59. pmc The mitochondrion: a perpetrator of acquired hearing loss
    Erik C Bottger
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland
    Hear Res 303:12-9. 2013
    ..Finally, we will detail recent advances in exploiting knowledge of aminoglycoside-mitochondria interactions for the development of non-ototoxic antibacterials. This article is part of a Special Issue entitled "Annual Reviews 2013". ..
  60. doi Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus
    Florian P Maurer
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastrasse 30 32, 8006 Zurich, Switzerland Nationales Zentrum für Mykobakterien, Universitat Zurich, Gloriastrasse 30 32, 8006 Zurich, Switzerland
    J Antimicrob Chemother 69:1559-63. 2014
    ..The aim of this work was to systematically study and compare drug susceptibility to clarithromycin and azithromycin in M. abscessus and Mycobacterium chelonae clinical isolates with a particular focus on inducible drug resistance...
  61. pmc Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods
    Michael Hombach
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland
    J Clin Microbiol 51:2385-7. 2013
    ..2%), Enterobacter cloacae (1.1%), Pseudomonas aeruginosa (0.7%), and Escherichia coli (0.4%). A total of 24% of Enterobacteriaceae MDR isolates and 12% of P. aeruginosa MDR isolates were categorized as MDR due to breakpoint changes...
  62. pmc Identification of Gram-positive cocci by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry: comparison of different preparation methods and implementation of a practical algorithm for routine diagnostics
    Bettina Schulthess
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
    J Clin Microbiol 51:1834-40. 2013
    ..We here suggest a practical algorithm for the clinical laboratory combining MALDI-TOF MS with phenotypic and molecular methods...
  63. pmc Systematic internal transcribed spacer sequence analysis for identification of clinical mold isolates in diagnostic mycology: a 5-year study
    Diana E Ciardo
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Gloriastr 30 32, 8006 Zurich, Switzerland
    J Clin Microbiol 48:2809-13. 2010
    ..This study is the first of its kind to testify to the systematic implementation of sequence-based identification procedures in the routine workup of mold isolates in the diagnostic mycology laboratory...
  64. doi Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis
    Peter Sander
    Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland Nationales Zentrum für Mykobakterien, Gloriastrasse 30 32, 8006 Zurich, Switzerland Electronic address
    Vaccine 33:1353-9. 2015
    ..Together, these results support the further development of BCG Δzmp1 for use in clinical trials. ..
  65. pmc In vivo efficacy of apramycin in murine infection models
    Martin Meyer
    Institut fur Medizinische Mikrobiologie, Nationales Zentrum für Mykobakterien, Universitat Zurich, Zurich, Switzerland
    Antimicrob Agents Chemother 58:6938-41. 2014
    ..These results suggest that apramycin has the potential to become a clinically useful agent against drug-resistant pathogens and support further development of this promising unique aminoglycoside. ..
  66. pmc Validation of antibiotic susceptibility testing guidelines in a routine clinical microbiology laboratory exemplifies general key challenges in setting clinical breakpoints
    Michael Hombach
    Institut fur Medizinische Mikrobiologie, Universitat Zurich, Zurich, Switzerland
    Antimicrob Agents Chemother 58:3921-6. 2014
    ....